382 related articles for article (PubMed ID: 35598462)
1. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
Calvi A; Tur C; Chard D; Stutters J; Ciccarelli O; Cortese R; Battaglini M; Pietroboni A; De Riz M; Galimberti D; Scarpini E; De Stefano N; Prados F; Barkhof F
Neuroimage Clin; 2022; 35():103048. PubMed ID: 35598462
[TBL] [Abstract][Full Text] [Related]
2. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
[TBL] [Abstract][Full Text] [Related]
3. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.
Calvi A; Clarke MA; Prados F; Chard D; Ciccarelli O; Alberich M; Pareto D; Rodríguez Barranco M; Sastre-Garriga J; Tur C; Rovira A; Barkhof F
Mult Scler; 2023 Mar; 29(3):352-362. PubMed ID: 36515487
[TBL] [Abstract][Full Text] [Related]
4. Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
Calvi A; Carrasco FP; Tur C; Chard DT; Stutters J; De Angelis F; John N; Williams T; Doshi A; Samson RS; MacManus D; Gandini Wheeler-Kingshott CA; Ciccarelli O; Chataway J; Barkhof F;
Neurology; 2022 Apr; 98(17):e1783-e1793. PubMed ID: 35277438
[TBL] [Abstract][Full Text] [Related]
5. Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
Preziosa P; Pagani E; Moiola L; Rodegher M; Filippi M; Rocca MA
Mult Scler; 2021 Sep; 27(10):1520-1532. PubMed ID: 33183125
[TBL] [Abstract][Full Text] [Related]
6. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL
Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027
[TBL] [Abstract][Full Text] [Related]
7. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
Arnold DL; Elliott C; Martin EC; Hyvert Y; Tomic D; Montalban X
Neurology; 2024 Mar; 102(5):e208058. PubMed ID: 38335474
[TBL] [Abstract][Full Text] [Related]
8. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Barkhof F; Schoonheim MM; Strijbis EM; Vrenken H; Gallo A; Bisecco A; Ciccarelli O; Yiannakas M; Rovira A; Sastre-Garriga J; Palace J; Matthews L; Gass A; Eisele P; Lukas C; Bellenberg B; Margoni M; Preziosa P; Filippi M;
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):10-18. PubMed ID: 36171105
[TBL] [Abstract][Full Text] [Related]
9. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal microstructural MRI markers of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: Magnetisation transfer, water diffusion and g-ratio.
York EN; Meijboom R; Thrippleton MJ; Bastin ME; Kampaite A; White N; Chandran S; Waldman AD;
Neuroimage Clin; 2022; 36():103228. PubMed ID: 36265199
[TBL] [Abstract][Full Text] [Related]
11. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
[TBL] [Abstract][Full Text] [Related]
12. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.
Calvi A; Mendelsohn Z; Hamed W; Chard D; Tur C; Stutters J; MacManus D; Kanber B; Wheeler-Kingshott CAMG; Barkhof F; Prados F
Eur J Neurol; 2024 Jan; 31(1):e16092. PubMed ID: 37823722
[TBL] [Abstract][Full Text] [Related]
13. CEST 2022 - Differences in APT-weighted signal in T1 weighted isointense lesions, black holes and normal-appearing white matter in people with relapsing-remitting multiple sclerosis.
Khormi I; Al-Iedani O; Casagranda S; Papageorgakis C; Alshehri A; Lea R; Liebig P; Ramadan S; Lechner-Scott J
Magn Reson Imaging; 2023 Oct; 102():212-221. PubMed ID: 37321380
[TBL] [Abstract][Full Text] [Related]
14. T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.
Thaler C; Faizy TD; Sedlacik J; Holst B; Stürner K; Heesen C; Stellmann JP; Fiehler J; Siemonsen S
AJNR Am J Neuroradiol; 2017 Feb; 38(2):264-269. PubMed ID: 28059711
[TBL] [Abstract][Full Text] [Related]
15. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities.
Traboulsee A; Dehmeshki J; Peters KR; Griffin CM; Brex PA; Silver N; Ciccarrelli O; Chard DT; Barker GJ; Thompson AJ; Miller DH
Mult Scler; 2003 Dec; 9(6):566-73. PubMed ID: 14664468
[TBL] [Abstract][Full Text] [Related]
16. Quantitative T
Harper JG; York EN; Meijboom R; Kampaite A; Thrippleton MJ; Kearns PKA; Valdés Hernández MDC; Chandran S; Waldman AD;
Eur Radiol; 2024 Jun; 34(6):3826-3839. PubMed ID: 37943312
[TBL] [Abstract][Full Text] [Related]
17. Quantitative susceptibility mapping of both ring and non-ring white matter lesions in relapsing remitting multiple sclerosis.
Coffman CH; White R; Subramanian K; Buch S; Bernitsas E; Haacke EM
Magn Reson Imaging; 2022 Sep; 91():45-51. PubMed ID: 35605736
[TBL] [Abstract][Full Text] [Related]
18. Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of "black holes".
Lapucci C; Romano N; Schiavi S; Saitta L; Uccelli A; Boffa G; Pardini M; Signori A; Castellan L; Inglese M; Roccatagliata L
Eur Radiol; 2020 Jul; 30(7):3843-3851. PubMed ID: 32162002
[TBL] [Abstract][Full Text] [Related]
19. Non-lesional white matter in relapsing-remitting multiple sclerosis assessed by multicomponent T2 relaxation.
Bontempi P; Rozzanigo U; Marangoni S; Fogazzi E; Ravanelli D; Cazzoletti L; Giometto B; Farace P
Brain Behav; 2023 Dec; 13(12):e3334. PubMed ID: 38041516
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid-In Gradient of Cortical and Deep Gray Matter Damage in Multiple Sclerosis.
Rubin M; Pagani E; Preziosa P; Meani A; Storelli L; Margoni M; Filippi M; Rocca MA
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200271. PubMed ID: 38896808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
